Physician profile
Ish Rawal
NPI 1467679589
$4,228.64
in general payments reported to CMS, 2019-2025
49 companies · $674 in 2025
The $674 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $613 · 2020: $278 · 2021: $516 · 2022: $619 · 2023: $688 · 2024: $841 · 2025: $674.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,203.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,202.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $711.33 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $449.24 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $314.28 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $301.55 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $234.85 | 2020-2025 | Austedo Xr, Ajovy, Austedo |
| Amarin Pharma, INC. | $191.78 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $155.33 | 2019-2023 | |
| Avanir Pharmaceuticals, INC. | $124.55 | 2020-2022 | |
| Lilly USA, LLC | $114.71 | 2022-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $99.06 | 2019-2025 | Arexvy, Shingrix, Bexsero |
| Ucb, INC. | $95.31 | 2021-2024 | Briviact, Zilbrysq |
| Exact Sciences Corporation | $93.62 | 2024-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.44 | 2022-2025 | Jardiance, Tradjenta |
| Lundbeck LLC | $86.11 | 2023-2025 | Rexulti |
| Astellas Pharma US INC | $85.75 | 2020-2024 | Veozah |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ish Rawal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.